# US 2023/0054339 A1 · Compositions and methods of modulating s-nitrosylation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054339 A1
- Document ID: US20230054339A1
- Status: Published application
- Kind: A1
- Application number: 17/899,121
- Filed: 2022-08-30
- Published: 2023-02-23
- Earliest claimed: 2014-12-05
- Assignees: Case Western Reserve University
- Applicants: Case Western Reserve University
- Inventors: Jonathan S. Stamler
- Web page: https://patentgrep.com/patent/US20230054339A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim at position 2

12: A method of treating at least one of congestive heart failure (CHF), cardiac hypertrophy, myocardial infarction, myocardial ischemia, myocardial ischemia reperfusion injury, cardiomyopathies, or arrhythmias in a subject in need thereof, the method comprising:
administering to the subject an AKR1A1 inhibitor at an amount effective to promote S-nitrosylation of proteins in the heart of the subject and treat the at least one of congestive heart failure (CHF), cardiac hypertrophy, myocardial infarction, myocardial ischemia, myocardial ischemia reperfusion injury, cardiomyopathies, or arrhythmias in the subject.

### Claim at position 3 (depends on 12)

13: The method of claim 12, wherein the AKR1A1 inhibitor is a SNO-CoAR inhibitor.

### Claim at position 4 (depends on 13)

14: The method of claim 13, wherein the AKR1A1 inhibitor includes imirestat or an analogue thereof.

### Claim at position 5 (depends on 14)

15: The method of claim 14, wherein the imirestat analogue is selected from the group consisting of:
R1, R2, R3, R4, R5, R6, and R7 are the same or different and are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-C24 alkyl, C2-C24 alkenyl, C2-C24 alkynyl, C3-C20 aryl, heterocycloalkenyl containing from 5-6 ring atoms, heteroaryl or heterocyclyl containing from 5-14 ring atoms, C6-C24 alkaryl, C6-C24 aralkyl, silyl, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C20 aryloxy, acyl, acyloxy, C2-C24 alkoxycarbonyl, C6-C20 aryloxycarbonyl, C2-C24 alkylcarbonato, C6-C20 arylcarbonato, carboxy, carboxylato, carbamoyl, C1-C24 alkyl-carbamoyl, arylcarbamoyl, carbamido, cyano, amino, C1-C24 alkyl amino, C5-C20 aryl amino, C2-C24 alkylamido, C6-C20 arylamido, sulfanamido, imino, alkylimino, arylimino, sulfo, sulfonato, C1-C24 alkylsulfanyl, arylsulfanyl, C1-C24 alkylsulfinyl, C5-C20 arylsulfinyl, C1-C24 alkylsulfonyl, C5-C20 arylsulfonyl, sulfonamide, and combinations thereof; and pharmaceutically acceptable salts thereof.

### Claim at position 6 (depends on 15)

16: The method of claim 15, wherein R1, R2, R3, R4, R5, R6, and R7 are the same or different are independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, cycloalkyl, heterocyclyl, heteroaryl, —OH, carboxyl, alkylene carboxyl, alkylene cycloalkyl, alkylene heterocyclyl, alkylene heteroaryl, alkylene-C(O)N(R8)m, —O-alkylene-carboxyl, —O-arylene-carboxyl, —O-alkylene-arylene, —O-alkylene-heteroaryl, —O-alkylene-heterocyclyl, carboxyl, alklyne carboxyl, —O-alkylene-N(R8)2, —N(R8)2, —N(R8)(alkylene-OH),
—C(O)N(R8)m, —C(O)N(R8)(alkylene-OH), —C(O)N(R8)(alkylene carboxyl), —C(O)N(R8)S(O)m-alkyl, —C(O)-alkyl, —C(O)O-alkyl, alkoxy, or —S(O)m-alkyl,
each R8 is independently, H, alkyl, -alkylene-OH optionally substituted with —OH, -alkylene-NH2, -alkylene-N(R9)2, -alkylene-O-alkylene-OH, -alkylene-O-alkylene-NH2, —C(O)-alkyl, —C(O)O-alkyl, -alkylene-COOH, or —S(O)m-alkyl;
or alternatively, two R8 together with the N atom to which they are attached can form a 4- to 7-membered heterocycle, optionally containing an additional heteroatom selected from O, S, or N, and wherein the heterocycle is optionally substituted with R9; and
R9 is halogen, alkyl, or alkoxy, m is 0, 1, or 2, and pharmaceutically acceptable salts thereof.

### Claim at position 7 (depends on 14)

17: The method of claim 14, wherein the imirestat analogue is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim at position 8 (depends on 12)

18: The method claim 12, wherein the AKR1A1 inhibitor can have a selectivity for AKR1A1 versus AKR1B1≥2 times.

### Claim at position 9 (depends on 12)

19: The method of claim 12, wherein a selective or partially selective AKR1A1 inhibitor is administered in combination with a selective or partially selective AKR1B1 inhibitor.

### Claim at position 10 (depends on 19)

20: The method of claim 19, wherein the AKR1B1 inhibitor can have a selectivity for AKR1B1 versus AKR1A1≥2 times.
